Literature DB >> 26493349

MMSA-1 expression pattern in multiple myeloma and its clinical significance.

Shan Meng1, Chenyang Lu1, Wanggang Zhang2, Wenjun Shen3, Yongchang Wei4, Dan Su1, Fuling Zhou5.   

Abstract

Multiple myeloma-associated antigen-1 (MMSA-1) is a novel multiple myeloma (MM)-associated antigen which has been recently identified. Herein, we have tried to examine its clinical significance by studying the relationship between its expression and selected clinicopathological features. We extracted mononuclear cells from the bone marrow of MM patients and healthy donors and compared the MMSA-1 expression by RT-PCR and Western blot analysis. In addition, we also analyzed MMSA-1 expression in patients that were grouped based on selected clinical parameters. Moreover, the impact of MMSA-1 on patients' survival was also explored. MMSA-1 mRNA and protein were significantly upregulated in MM patients in comparison with healthy donors. Moreover, among the newly diagnosed and relapsed/refractory patients, the MMSA-1 expression was higher in relapsed/refractory patients. In addition, MMSA-1 mRNA expression not only showed significantly higher correlation with clinical parameters such as age, Durie and Salmon stage, bone lesion condition, albumin, creatinine and lactate dehydrogenase but also has a close relationship with myeloma bone disease-related cytokines, genetic abnormalities and treatment response. Multivariate COX analysis predicted MMSA-1 and LDH levels to be independently associated with a poor progression-free survival and overall survival in myeloma patients. Our findings provide initial proof of concept that MMSA-1 is a potent gene that is specifically expressed in MM patients and could be a feasible biomarker and independent prognostic factor.

Entities:  

Keywords:  Hematological malignancy; LDH; MMSA-1; Multiple myeloma

Mesh:

Substances:

Year:  2015        PMID: 26493349     DOI: 10.1007/s10238-015-0393-y

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  52 in total

1.  [Immunological screening for multiple myeloma-associated antigens and their bioinformatics analysis].

Authors:  Fu-Ling Zhou; Wang-Gang Zhang; Gang Chen; Wan-Hong Zhao; Xing-Mei Cao; Yin-Xia Chen; Wei Tian; Su-Hu Liu; Ming-Xia Wu; Ming Liu
Journal:  Zhongguo Shi Yan Xue Ye Xue Za Zhi       Date:  2006-04

2.  Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma.

Authors:  Pavel P Kotouček; Alberto Orfao
Journal:  Br J Haematol       Date:  2014-04-02       Impact factor: 6.998

3.  [Multiple myeloma stem cell].

Authors:  Naoki Hosen
Journal:  Nihon Rinsho       Date:  2015-01

Review 4.  [Supportive care in multiple myeloma for continuing anti-myeloma therapies].

Authors:  Hirohiko Shibayama
Journal:  Rinsho Ketsueki       Date:  2014-10

5.  Serological identification and bioinformatics analysis of immunogenic antigens in multiple myeloma.

Authors:  F L Zhou; W G Zhang; G Chen; W H Zhao; X M Cao; Y X Chen; W Tian; J Liu; S H Liu
Journal:  Cancer Immunol Immunother       Date:  2005-09-29       Impact factor: 6.968

6.  Factors affecting outcome of patients with multiple myeloma.

Authors:  Abdul Basit; Neelam Siddiqui; Abdul Hameed; Narjis Muzaffar; Sohail Athar
Journal:  J Ayub Med Coll Abbottabad       Date:  2014 Jul-Sep

7.  Incidence and prognostic value of recurrent chromosomal abnormalities in elderly patients with multiple myeloma.

Authors:  Esteban Braggio
Journal:  Future Oncol       Date:  2013-12       Impact factor: 3.404

8.  Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study.

Authors:  Milena Sant; Pamela Minicozzi; Morgane Mounier; Lesley A Anderson; Hermann Brenner; Bernd Holleczek; Rafael Marcos-Gragera; Marc Maynadié; Alain Monnereau; Gemma Osca-Gelis; Otto Visser; Roberta De Angelis
Journal:  Lancet Oncol       Date:  2014-07-13       Impact factor: 41.316

9.  Bortezomib-thalidomide-based regimens improved clinical outcomes without increasing toxicity as induction treatment for untreated multiple myeloma: a meta-analysis of phase III randomized controlled trials.

Authors:  Hejing Huang; Lili Zhou; Lihui Peng; Weijun Fu; Chunyang Zhang; Jian Hou
Journal:  Leuk Res       Date:  2014-06-30       Impact factor: 3.156

Review 10.  Diagnosis and risk stratification in multiple myeloma.

Authors:  Niels W C J van de Donk; Pieter Sonneveld
Journal:  Hematol Oncol Clin North Am       Date:  2014-07-22       Impact factor: 3.722

View more
  2 in total

Review 1.  Protein palmitoylation and cancer.

Authors:  Pin-Joe Ko; Scott J Dixon
Journal:  EMBO Rep       Date:  2018-09-19       Impact factor: 8.807

Review 2.  Current treatment options of T cell-associated immunotherapy in multiple myeloma.

Authors:  Hailing Liu; Yunbao Pan; Shan Meng; Wanggang Zhang; Fuling Zhou
Journal:  Clin Exp Med       Date:  2017-01-24       Impact factor: 3.984

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.